Relief Factor an over-the-counter supplement marketed for joint and muscle discomfort.
Relief Factor is a commercial over-the-counter dietary supplement marketed for joint and muscle pain and inflammation, not an FDA-approved drug and not a term with a formal medical definition.
It’s a daily packet of ingredients like turmeric extract, omega-3 fish oil, resveratrol, and icariin (epimedium), and it’s sold mostly through a subscription model with a ~3-week “QuickStart” trial.
Some of the individual ingredients (especially omega-3s and turmeric/curcumin) have modest evidence for mild inflammation or joint pain, but the branded product itself has little independent clinical research.
Most of its support is company-sponsored surveys and testimonials.
No clinical trials of the branded Relief Factor product itself are identified
These agents are generally well tolerated.
Note that high-dose fish oil can affect bleeding/platelet function (relevant with anticoagulants), curcumin can cause GI upset and may interact with anticoagulants, and supplement quality/standardization varies since these products are not FDA-regulated as drugs.
Turmeric and fish oil can affect blood clotting.
Curcumin (turmeric) has the strongest supporting data.
11 meta-analyses found significant reductions in pain, function, and stiffness scores, and a Bayesian network meta-analysis of 23 RCTs reported pain reduction of −1.63 and WOMAC total improvement of −18.85 versus placebo, with fewer adverse events than NSAIDs.
The 2026 guidelines states curcumin is an effective, safe adjunct, with efficacy comparable to NSAIDs but fewer GI effects.
Omega-3 fish oil can modestly reduce OA pain and NSAID use in several trials, though evidence quality is low and heterogeneous, and one RCT found low-dose outperformed high-dose fish oil.
Resveratrol as an adjunct (500 mg/day with meloxicam) significantly improved knee OA pain and function in a randomized placebo-controlled trial; most other data are preclinical/mechanistic.
Icariin/epimedium — no clinical trial evidence in OA or joint pain was identified in the retrieved literature; its inclusion is not supported by robust human data.
Each ingredient has at least some supportive evidence individually, but the branded combination has not been tested in published clinical trials, and typical effective doses in trials (e.g., curcumin ~1,000 mg/day of standardized extract; boswellia-type doses) may differ from amounts in the proprietary blend, which are not always disclosed.
For OA, guideline-supported foundational therapy remains exercise, weight management, topical/oral NSAIDs, and physical therapy; nutraceuticals like these are best positioned as adjuncts.